Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bilastine pharmacokinetics and safety in children aged 2–5 years with allergic rhinoconjunctivitis or urticaria
2021-003011-26Phase 3Completed
- Sponsor
- Faes Farma
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bilastine in allergic rhinoconjunctivitis (ARC) and urticaria, sponsored by Faes Farma. Primary endpoint: Bilastine plasma concentration. Started Sep 2021; status: completed.
02
Drugs
bilastine
03
Conditions
allergic rhinoconjunctivitis (ARC)urticaria
Beyond the preview
Go deeper on 2021-003011-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003011-26.